Unicycive Therapeutics, Inc. (UNCY) Stock Forecast
Data as of May 10, 2026Healthcare · Current price $7.88 (+0.25%)
Consensus Target
—
Upside
—
Analysts
2
Rating
Buy(2.00)
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
No analyst price targets available.
UNCY vs Sector & Market
| Metric | UNCY | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 2 | 8 | 19 |
| Target Upside | — | +1708.8% | +16.4% |
| P/E Ratio | -42.90 | 3.34 | 27.60 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $7M | $72M | $183M | 6 |
| 2027-03-31 | $198M | $198M | $198M | 4 |
| 2027-06-30 | $257M | $257M | $257M | 3 |
| 2027-09-30 | $295M | $295M | $295M | 3 |
| 2027-12-31 | $388M | $388M | $388M | 3 |
| 2028-03-31 | $56M | $56M | $56M | 2 |
| 2028-06-30 | $58M | $58M | $58M | 5 |
| 2028-09-30 | $63M | $63M | $63M | 4 |
| 2028-12-31 | $65M | $65M | $65M | 4 |
| 2029-12-31 | $107M | $614M | $1.45B | 2 |
| 2030-12-31 | $117M | $668M | $1.58B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.12 | $0.06 | $0.41 | 5 |
| 2027-03-31 | $4.72 | $4.72 | $4.72 | 1 |
| 2027-06-30 | $5.98 | $5.98 | $5.98 | 1 |
| 2027-09-30 | $6.59 | $6.59 | $6.59 | 1 |
| 2027-12-31 | $8.41 | $8.41 | $8.41 | 1 |
| 2028-03-31 | $0.00 | $0.00 | $0.00 | 2 |
| 2028-06-30 | $0.00 | $0.00 | $0.00 | 2 |
| 2028-09-30 | $0.00 | $0.00 | $0.00 | 2 |
| 2028-12-31 | $0.00 | $0.00 | $0.00 | 2 |
| 2029-12-31 | $-0.72 | $9.96 | $27.65 | 2 |
| 2030-12-31 | $-0.78 | $10.72 | $29.76 | 2 |
Frequently Asked Questions
What is the analyst consensus for UNCY?
The consensus among 2 analysts covering Unicycive Therapeutics, Inc. (UNCY) is Buy with an average price target of N/A.
How many analysts cover UNCY?
2 analysts have issued ratings for Unicycive Therapeutics, Inc. in the past 12 months.
Is UNCY a buy or sell right now?
Based on 2 analyst ratings, UNCY has a consensus rating of Buy (2.00/5) with a N/A upside to the consensus target of N/A.
What are the earnings estimates for UNCY?
Analysts estimate UNCY will report EPS of $0.06 for the period ending 2026-12-31, with revenue estimated at $72M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.